Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
Well-capitalized into 2026 with ability to fully fund lead asset EryDex expected through Phase 3 trial under special protocol assessment and to NDA submission EryDex utilizes autologous...
Dirk Thye Luca Benatti David Lamond European Investment Bank International Cooperative Ataxia Rating Scale Rm European Medicines Agency
Source: marketscreener.com